A Healthy Trade (In More Ways Than One)
With the IBB biotechnology ETF poised to have its best quarter in six years and analysts seeing further upside for the space, biotech appears to… Read More »A Healthy Trade (In More Ways Than One)
With the IBB biotechnology ETF poised to have its best quarter in six years and analysts seeing further upside for the space, biotech appears to… Read More »A Healthy Trade (In More Ways Than One)
After a rough end to 2018, with massive fund outflows in the fourth quarter, biotech’s condition has been improving in 2019 – and these two… Read More »Biotech’s 2019 “Plot Twist”
After finding itself among the most oversold sectors last year, biotech is having its best start to a year since 2012 – a rally fueled… Read More »Biotech Is On The Mend
This biotech company’s drug for treating hypoactive sexual desire disorder in women is expected to receive FDA approval in early January 2019. With increasing market… Read More »The New – And More Effective – Female Viagra: An Attractive Opportunity?
There are very few diseases for which actual cures have been developed – but that could soon start to change. And with a “golden age… Read More »The New Paradigm For Biotech Investing
These three stocks – including a clinical-stage biotech with a still-promising drug candidate – may be under-performing at the moment, but some of Wall Street’s… Read More »Bargain Bin & Analyst Adored